OCEA

Ocean Biomedical (OCEA)

Ocean Biomedical Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:OCEA

1 2 3 4 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/06/05	20:01	GlobeNewswire Inc.	Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results from Their Lead Checkpoint Modifier-Containing Immunotherapy, VRON-0200, for HBV Functional Cure, at EASL 2024	NASDAQ:OCEA	Ocean Biomedical Inc
2024/05/30	20:44	GlobeNewswire Inc.	Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q	NASDAQ:OCEA	Ocean Biomedical Inc
2024/05/16	21:01	GlobeNewswire Inc.	Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential Capability to Protect Against Infection and Treat Severe Disease	NASDAQ:OCEA	Ocean Biomedical Inc
2024/04/25	05:51	GlobeNewswire Inc.	Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K	NASDAQ:OCEA	Ocean Biomedical Inc
2024/03/28	21:01	GlobeNewswire Inc.	Ocean Biomedical (NASDAQ: OCEA) Congratulates JV Partner, Virion Therapeutics, on Promising First-Ever Human Phase 1B Clinical Safety Data for Their Lead Checkpoint Modifier-Containing Immunotherapy for HBV Functional Cure, at Global APASL	NASDAQ:OCEA	Ocean Biomedical Inc
2024/03/09	07:00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:OCEA	Ocean Biomedical Inc
2024/03/05	07:22	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:OCEA	Ocean Biomedical Inc
2024/02/29	22:01	GlobeNewswire Inc.	Ocean Biomedical (NASDAQ: OCEA) Announces Joint Venture Partner, Virion Therapeutics to Present Their First Clinical Study Data as an Accepted Late Breaker Presentation at 2024 APASL Global Liver Meeting	NASDAQ:OCEA	Ocean Biomedical Inc
2024/02/14	08:43	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:OCEA	Ocean Biomedical Inc
2024/01/20	07:05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:OCEA	Ocean Biomedical Inc
2024/01/18	06:05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:OCEA	Ocean Biomedical Inc
2023/12/05	22:15	GlobeNewswire Inc.	Ocean Biomedical, Inc. Announces Publication of Groundbreaking Breast Cancer Research Uncovering a New Tumor Suppression Pathway for Its Proprietary Anti-Chi3L1 Antibody	NASDAQ:OCEA	Ocean Biomedical Inc
2023/11/30	07:41	GlobeNewswire Inc.	Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q	NASDAQ:OCEA	Ocean Biomedical Inc
2023/11/15	20:20	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:OCEA	Ocean Biomedical Inc
2023/11/15	20:20	Edgar (US Regulatory)	Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB	NASDAQ:OCEA	Ocean Biomedical Inc
2023/11/14	22:01	GlobeNewswire Inc.	Ocean Biomedical (NASDAQ: OCEA) Announces Positive Preclinical Oncology Data for VRON-0300, Presented at SITC 2023 Annual Meeting, and Clinical Updates by 50/50 Joint Venture Partner Virion Therapeutics	NASDAQ:OCEA	Ocean Biomedical Inc
2023/10/26	18:30	GlobeNewswire Inc.	Ocean Biomedical (NASDAQ: OCEA) Announces First Patients Dosed by Joint Venture Partner Virion Therapeutics in Phase 1b Study of Novel Immunotherapy for Chronic Hepatitis B Virus Infection	NASDAQ:OCEA	Ocean Biomedical Inc
2023/10/26	18:30	PR Newswire (US)	Virion Therapeutics and Joint Venture Partner, Ocean Biomedical (NASDAQ: OCEA), Announce First Patients Dosed with Novel Immunotherapy Evaluating a Functional Cure for Chronic Hepatitis B Virus Infection	NASDAQ:OCEA	Ocean Biomedical Inc
2023/10/24	19:30	GlobeNewswire Inc.	Ocean Biomedical (NASDAQ: OCEA) Announces $1 Million Falk Award for Malaria Drug Candidate Addressing Evolving Resistance to Artemisinin-Based Therapeutics to Chief Scientist Dr. Jonathan Kurtis	NASDAQ:OCEA	Ocean Biomedical Inc
2023/10/17	21:01	GlobeNewswire Inc.	Ocean Biomedical (NASDAQ: OCEA) Announces Enrollment of Patients for Phase 1b Study for Chronic Hepatitis B Treatment in 50-50 Joint Venture with Virion Therapeutics	NASDAQ:OCEA	Ocean Biomedical Inc
2023/10/13	06:10	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:OCEA	Ocean Biomedical Inc
2023/10/12	21:01	GlobeNewswire Inc.	Ocean Biomedical and Virion Therapeutics Form Joint Venture Supporting Multi-National, First-In-Humans Clinical Chronic Hepatitis B Study: Now Enrolling, With Goal of a Functional Cure for a Disease Affecting 300+ Million Patients Worldwide	NASDAQ:OCEA	Ocean Biomedical Inc
2023/10/12	21:01	PR Newswire (US)	Virion Therapeutics and Ocean Biomedical form joint venture supporting multi-national, first-in-humans clinical chronic hepatitis B study: now enrolling, with goal of a functional cure for a disease affecting 300+ million patients worldwide	NASDAQ:OCEA	Ocean Biomedical Inc
2023/10/07	06:25	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:OCEA	Ocean Biomedical Inc
2023/10/05	05:56	GlobeNewswire Inc.	Updated: Ocean Biomedical Announces Non-Dilutive Amendment to Existing Agreement with Polar Multi-Strategy Master Fund	NASDAQ:OCEA	Ocean Biomedical Inc
2023/10/04	21:01	GlobeNewswire Inc.	Ocean Biomedical Announces Loan Commitment from Largest Stockholder; Up to $10 Million	NASDAQ:OCEA	Ocean Biomedical Inc
2023/10/04	03:30	GlobeNewswire Inc.	Ocean Biomedical Announces Non-Dilutive Amendment to Existing Agreement with a Key Financing Partner	NASDAQ:OCEA	Ocean Biomedical Inc
2023/10/03	21:01	GlobeNewswire Inc.	Ocean Biomedical Announces Newly Published Findings Demonstrating Ability to Restore Treatment Sensitivity to AstraZeneca’s Leading Lung Cancer Drug After Resistance Has Formed, and Enhanced Tumor Suppression in EGFR-Mutation Lung Cancers	NASDAQ:OCEA	Ocean Biomedical Inc
2023/09/14	21:01	GlobeNewswire Inc.	Ocean Biomedical (NASDAQ: OCEA) Will Host an R&D Update Today on Malaria, and Fibrosis Programs with Scientific Co-founders Jack A. Elias, MD, and Jonathan Kurtis, MD PhD.	NASDAQ:OCEA	Ocean Biomedical Inc
2023/09/07	06:25	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:OCEA	Ocean Biomedical Inc